Laboratory of Physiopharmacology, University of Antwerp, Belgium (G.W.D.K., E.F., L.D., H.S., Z.V., V.F.M.S.).
Department of Cardiology, ZNA Hospital, Antwerp, Belgium (G.W.D.K.).
Circ Heart Fail. 2019 Oct;12(10):e006288. doi: 10.1161/CIRCHEARTFAILURE.119.006288. Epub 2019 Oct 14.
Heart failure is a complex syndrome whose phenotypic presentation and disease progression depends on a complex network of adaptive and maladaptive responses. One of these responses is the endothelial release of NRG (neuregulin)-1-a paracrine growth factor activating ErbB2 (erythroblastic leukemia viral oncogene homolog B2), ErbB3, and ErbB4 receptor tyrosine kinases on various targets cells. NRG-1 features a multitasking profile tuning regenerative, inflammatory, fibrotic, and metabolic processes. Here, we review the activities of NRG-1 on different cell types and organs and their implication for heart failure progression and its comorbidities. Although, in general, effects of NRG-1 in heart failure are compensatory and beneficial, translation into therapies remains unaccomplished both because of the complexity of the underlying pathways and because of the challenges in the development of therapeutics (proteins, peptides, small molecules, and RNA-based therapies) for tyrosine kinase receptors. Here, we give an overview of the complexity to be faced and how it may be tackled.
心力衰竭是一种复杂的综合征,其表型表现和疾病进展取决于适应性和失调性反应的复杂网络。其中一种反应是内皮细胞释放 NRG(神经调节蛋白)-1,一种旁分泌生长因子,可激活各种靶细胞上的 ErbB2(红细胞生成素样病毒癌基因同源物 B2)、ErbB3 和 ErbB4 受体酪氨酸激酶。NRG-1 具有多任务功能,可调节再生、炎症、纤维化和代谢过程。在这里,我们回顾了 NRG-1 在不同细胞类型和器官上的活性及其对心力衰竭进展及其合并症的影响。尽管 NRG-1 在心力衰竭中的作用通常是代偿性和有益的,但由于潜在途径的复杂性以及治疗学(蛋白质、肽、小分子和基于 RNA 的治疗)的发展面临挑战,转化为治疗方法仍未实现。在这里,我们概述了所面临的复杂性以及如何解决这些问题。